Brennan, C. A. & Garrett, W. S. Fusobacterium nucleatumâsymbiont, opportunist and oncobacterium. Nat. Rev. Microbiol. 17, 156â166 (2019).
Janney, A., Powrie, F. & Mann, E. H. Host-microbiota maladaptation in colorectal cancer. Nature 585, 509â517 (2020).
OâKeefe, S. J. Diet, microorganisms and their metabolites, and colon cancer. Nat. Rev. Gastroenterol. Hepatol. 13, 691â706 (2016).
Tilg, H., Adolph, T. E., Gerner, R. R. & Moschen, A. R. The intestinal microbiota in colorectal cancer. Cancer Cell 33, 954â964 (2018).
Wong, S. H. & Yu, J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat. Rev. Gastroenterol. Hepatol. 16, 690â704 (2019).
Pleguezuelos-Manzano, C. et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature 580, 269â273 (2020).
Slowicka, K. et al. Zeb2 drives invasive and microbiota-dependent colon carcinoma. Nat. Cancer 1, 620â634 (2020).
Morgan, E. et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72, 338â344 (2023).
Keum, N. & Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 16, 713â732 (2019).
GBD 2019 Colorectal Cancer Collaborators. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990â2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 4, 913â933 (2019).
Zepeda-Rivera, M. et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature https://doi.org/10.1038/s41586-024-07182-w (2024).
Buc, E. et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS ONE 8, e56964 (2013).
Arthur, J. C. et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 5, 4724 (2014).
Dejea, C. M. et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359, 592â597 (2018).
Nougayrede, J. P. et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313, 848â851 (2006).
Cuevas-Ramos, G. et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc. Natl Acad. Sci. USA 107, 11537â11542 (2010).
Rosendahl Huber, A. et al. Improved detection of colibactin-induced mutations by genotoxic E. coli in organoids and colorectal cancer. Cancer Cell 42, 487â496 (2024).
Cougnoux, A. et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 63, 1932â1942 (2014).
Brugiroux, S. et al. Genome-guided design of a defined mouse microbiota that confers colonization resistance against Salmonella enterica serovar Typhimurium. Nat. Microbiol. 2, 16215 (2016).
Bonnet, M. et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin. Cancer Res. 20, 859â867 (2014).
Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120â123 (2012).
Tomkovich, S. et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. Cancer Res. 77, 2620â2632 (2017).
Salesse, L. et al. Colibactin-producing Escherichia coli induce the formation of invasive carcinomas in a chronic inflammation-associated mouse model. Cancers 13, 2060 (2021).
Lucas, C. et al. Autophagy of intestinal epithelial cells inhibits colorectal carcinogenesis induced by colibactin-producing Escherichia coli in ApcMin/+ mice. Gastroenterology 158, 1373â1388 (2020).
Li, Z. R. et al. Divergent biosynthesis yields a cytotoxic aminomalonate-containing precolibactin. Nat. Chem. Biol. 12, 773â775 (2016).
Wernke, K. M. et al. Structure and bioactivity of colibactin. Bioorg. Med. Chem. Lett. 30, 127280 (2020).
Conover, M. S. et al. Inflammation-induced adhesin-receptor interaction provides a fitness advantage to uropathogenic E. coli during chronic infection. Cell Host Microbe 20, 482â492 (2016).
Jones, C. H. et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc. Natl Acad. Sci. USA 92, 2081â2085 (1995).
Kalas, V. et al. Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection. Proc. Natl Acad. Sci. USA 115, E2819âE2828 (2018).
Maddirala, A. R. et al. Biphenyl Gal and GalNAc FmlH lectin antagonists of uropathogenic E. coli (UPEC): optimization through iterative rational drug design. J. Med. Chem. 62, 467â479 (2019).
Stentebjerg-Olesen, B., Chakraborty, T. & Klemm, P. Type 1 fimbriation and phase switching in a natural Escherichia coli fimB null strain, Nissle 1917. J. Bacteriol. 181, 7470â7478 (1999).
Dreux, N. et al. Point mutations in FimH adhesin of Crohnâs disease-associated adherent-invasive Escherichia coli enhance intestinal inflammatory response. PLoS Pathog. 9, e1003141 (2013).
Iebba, V. et al. Microevolution in fimH gene of mucosa-associated Escherichia coli strains isolated from pediatric patients with inflammatory bowel disease. Infect. Immun. 80, 1408â1417 (2012).
Schwartz, D. J. et al. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proc. Natl Acad. Sci. USA 110, 15530â15537 (2013).
Reinisch, W. et al. Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohnâs disease. J. Gastroenterol. Hepatol. 37, 832â840 (2022).
Chevalier, G. et al. Blockage of bacterial FimH prevents mucosal inflammation associated with Crohnâs disease. Microbiome 9, 176 (2021).
Reuter, C., Alzheimer, M., Walles, H. & Oelschlaeger, T. A. An adherent mucus layer attenuates the genotoxic effect of colibactin. Cell Microbiol. https://doi.org/10.1111/cmi.12812 (2018).
Zhao, Z., Xu, S., Zhang, W., Wu, D. & Yang, G. Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications. Food Funct. 13, 5914â5924 (2022).
Olier, M. et al. Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity. Gut Microbes 3, 501â509 (2012).
Giaffer, M. H., Holdsworth, C. D. & Duerden, B. I. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 33, 646â650 (1992).
Darfeuille-Michaud, A. et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohnâs disease. Gastroenterology 115, 1405â1413 (1998).
Harnack, C. et al. Short-term mucosal disruption enables colibactin-producing E. coli to cause long-term perturbation of colonic homeostasis. Gut Microbes 15, 2233689 (2023).
van der Post, S. et al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut 68, 2142â2151 (2019).
Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167, 1339â1353 (2016).
Dalmasso, G. et al. Colibactin-producing Escherichia coli enhance resistance to chemotherapeutic drugs by promoting epithelial to mesenchymal transition and cancer stem cell emergence. Gut Microbes 16, 2310215 (2024).
de Oliveira Alves, N. et al. The colibactin-producing Escherichia coli alters the tumor microenvironment to immunosuppressive lipid overload facilitating colorectal cancer progression and chemoresistance. Gut Microbes 16, 2320291 (2024).
Volpe, M. R. et al. A small molecule inhibitor prevents gut bacterial genotoxin production. Nat. Chem. Biol. 19, 159â167 (2023).
Blanco-Miguez, A. et al. Targeted depletion of pks+ bacteria from a fecal microbiota using specific antibodies. mSystems 8, e0007923 (2023).
Gencay, Y. E. et al. Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01759-y (2023).
Spaulding, C. N. et al. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature 546, 528â532 (2017).
Greene, S. E., Hibbing, M. E., Janetka, J., Chen, S. L. & Hultgren, S. J. Human urine decreases function and expression of type 1 pili in uropathogenic Escherichia coli. mBio 6, e00820 (2015).
Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl Acad. Sci. USA 97, 6640â6645 (2000).
Ramesh, P., Kirov, A. B., Huels, D. J. & Medema, J. P. Isolation, propagation, and clonogenicity of intestinal stem cells. Methods Mol. Biol. 2002, 61â73 (2019).
Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047â3048 (2016).
Andrews, S. FastQC: a quality control tool for high throughput sequence data (2010).
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114â2120 (2014).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15â21 (2013).
Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, giab008 (2021).
Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
Love MI, A. S., Kim, V. & Huber, W. RNA-seq workflow: gene-level exploratory analysis and differential expression. F1000Research 4, 1070 (2016).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https://doi.org/10.1101/060012 (2019).
Stephens, M. False discovery rates: a new deal. Biostatistics 18, 275â294 (2017).
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).
Kolde, R. Pheatmap: pretty heatmaps (2012).
Thakur, S. D., Obradovic, M., Dillon, J. R., Ng, S. H. & Wilson, H. L. Development of flow cytometry based adherence assay for Neisseria gonorrhoeae using 5â²-carboxyfluorosceinsuccidyl ester. BMC Microbiol. 19, 67 (2019).
Martin, H. M. et al. Enhanced Escherichia coli adherence and invasion in Crohnâs disease and colon cancer. Gastroenterology 127, 80â93 (2004).
Wirth, T. et al. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol. Microbiol. 60, 1136â1151 (2006).
Vizcaino, M. I., Engel, P., Trautman, E. & Crawford, J. M. Comparative metabolomics and structural characterizations illuminate colibactin pathway-dependent small molecules. J. Am. Chem. Soc. 136, 9244â9247 (2014).
